Compare Stocks: RIGL, GRAL, DYN, and DNLI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$20.38 -4.0%	$23.81	$12.58 ▼ $27.30	$3.39B	1.01	1.12 million shs	1.84 million shs
DYN Dyne Therapeutics	$17.90 -3.3%	$24.38	$11.92 ▼ $27.31	$3.46B	1.08	2.84 million shs	3.02 million shs
GRAL GRAIL	$75.89 +0.5%	$73.77	$36.98 ▼ $118.84	$3.37B	3.25	617,014 shs	1.51 million shs
RIGL Rigel Pharmaceuticals	$44.36 -2.2%	$42.88	$24.95 ▼ $52.24	$839.07M	1.2	256,777 shs	269,882 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+0.62%	-4.76%	-13.03%	-3.24%	+49.54%
DYN Dyne Therapeutics	+1.70%	-23.72%	-27.94%	+2.49%	+40.84%
GRAL GRAIL	-0.92%	-5.99%	+11.29%	+29.58%	+98.55%
RIGL Rigel Pharmaceuticals	-4.00%	-6.82%	+6.51%	+39.71%	+19.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$20.38 -4.0%	$23.81	$12.58 ▼ $27.30	$3.39B	1.01	1.12 million shs	1.84 million shs
DYN Dyne Therapeutics	$17.90 -3.3%	$24.38	$11.92 ▼ $27.31	$3.46B	1.08	2.84 million shs	3.02 million shs
GRAL GRAIL	$75.89 +0.5%	$73.77	$36.98 ▼ $118.84	$3.37B	3.25	617,014 shs	1.51 million shs
RIGL Rigel Pharmaceuticals	$44.36 -2.2%	$42.88	$24.95 ▼ $52.24	$839.07M	1.2	256,777 shs	269,882 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+0.62%	-4.76%	-13.03%	-3.24%	+49.54%
DYN Dyne Therapeutics	+1.70%	-23.72%	-27.94%	+2.49%	+40.84%
GRAL GRAIL	-0.92%	-5.99%	+11.29%	+29.58%	+98.55%
RIGL Rigel Pharmaceuticals	-4.00%	-6.82%	+6.51%	+39.71%	+19.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.85	75.89% Upside
DYN Dyne Therapeutics	2.81	Moderate Buy	$32.17	79.70% Upside
GRAL GRAIL	2.36	Hold	$71.11	-6.30% Downside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	33.00% Upside

Current Analyst Ratings Breakdown

Latest RIGL, GRAL, DYN, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/9/2026	DYN Dyne Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$45.00 ➝ $36.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
9/9/2026	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $26.00
9/9/2026	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$35.00 ➝ $30.00
9/9/2026	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Underweight	$17.00 ➝ $10.00
9/9/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$105.00
9/8/2026	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$37.00
8/25/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/25/2026	DNLI Denali Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $35.00
8/17/2026	RIGL Rigel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$40.00 ➝ $49.00

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	9.86	N/A	N/A	$6.91 per share	2.95
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
GRAL GRAIL	$147.17M	23.03	N/A	N/A	$66.13 per share	1.15
RIGL Rigel Pharmaceuticals	$294.28M	2.79	$6.59 per share	6.73	$21.57 per share	2.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.72	10.27	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)

Latest RIGL, GRAL, DYN, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	0.01	8.37	8.32
DYN Dyne Therapeutics	0.28	12.02	12.02
GRAL GRAIL	N/A	10.95	10.95
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
DYN Dyne Therapeutics	96.68%
GRAL GRAIL	N/A
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	9.70%
DYN Dyne Therapeutics	9.46%
GRAL GRAIL	1.83%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	507	159.85 million	144.34 million	Optionable
DYN Dyne Therapeutics	258	186.75 million	169.08 million	Optionable
GRAL GRAIL	910	44.67 million	43.85 million	Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable

RIGL, GRAL, DYN, and DNLI Headlines

Recent News About These Companies

Rigel Pharmaceuticals op H.C. Wainwright-conferentie: groeiplan verbreed

September 15 at 5:32 PM | nl.investing.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

September 15 at 10:40 AM | seekingalpha.com

Squarepoint Ops LLC Acquires 38,550 Shares of Rigel Pharmaceuticals, Inc. $RIGL

September 14 at 4:16 AM | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) and Aclaris Therapeutics (NASDAQ:ACRS) Critical Contrast

September 11, 2026 | americanbankingnews.com

Bank of New York Mellon Corp Purchases Shares of 108,209 Rigel Pharmaceuticals, Inc. $RIGL

September 6, 2026 | marketbeat.com

Man Group plc Invests $814,000 in Rigel Pharmaceuticals, Inc. $RIGL

September 4, 2026 | marketbeat.com

Rigel to Participate in Upcoming September Investor Conferences

September 2, 2026 | prnewswire.com

Jupiter Topco LLC Invests $3.45 Million in Rigel Pharmaceuticals, Inc. $RIGL

September 2, 2026 | marketbeat.com

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

September 2, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL

August 30, 2026 | marketbeat.com

Bank of America Corp DE Has $3.90 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGL

August 30, 2026 | marketbeat.com

OMERS ADMINISTRATION Corp Invests $2.03 Million in Rigel Pharmaceuticals, Inc. $RIGL

August 27, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Moderate Buy" by Brokerages

August 26, 2026 | marketbeat.com

Globeflex Capital L P Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 24, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research

August 19, 2026 | marketbeat.com

HC Wainwright Analysts Increase Earnings Estimates for RIGL

August 18, 2026 | marketbeat.com

Rigel Pharmaceuticals

August 17, 2026 | money.usnews.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13, 2026 | prnewswire.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RIGL, GRAL, DYN, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$20.38 -0.84 (-3.96%)

Closing price 04:00 PM Eastern

Extended Trading

$21.05 +0.67 (+3.29%)

As of 07:30 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Dyne Therapeutics NASDAQ:DYN

$17.90 -0.62 (-3.35%)

Closing price 04:00 PM Eastern

Extended Trading

$17.89 -0.01 (-0.06%)

As of 07:30 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

GRAIL NASDAQ:GRAL

$75.89 +0.36 (+0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$76.27 +0.38 (+0.50%)

As of 07:57 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Rigel Pharmaceuticals NASDAQ:RIGL

$44.36 -0.99 (-2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$44.36 0.00 (0.00%)

As of 07:30 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RIGL, GRAL, DYN, and DNLI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RIGL, GRAL, DYN, and DNLI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RIGL, GRAL, DYN, and DNLI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RIGL, GRAL, DYN, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Dyne Therapeutics NASDAQ:DYN

GRAIL NASDAQ:GRAL

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RIGL, GRAL, DYN, and DNLI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RIGL, GRAL, DYN, and DNLI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RIGL, GRAL, DYN, and DNLI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RIGL, GRAL, DYN, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

Dyne Therapeutics NASDAQ:DYN

GRAIL NASDAQ:GRAL

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools